Paras Healthcare IPO: Company Files DRHP with SEBI to Raise ₹1,800 Crore via Public Issue

Why It Matters

The IPO gives Paras Healthcare capital to accelerate its expansion in a fast‑growing Indian tertiary‑care market, while offering investors exposure to a high‑margin, volume‑driven healthcare platform. Successful fundraising could set a benchmark for other specialty hospital groups seeking public market funding.

Key Takeaways

• Paras Healthcare seeks up to $217 million via IPO, ₹1,800 crore total.
• Fresh issue of $60 million; shareholders selling $157 million of shares.
• Plans add 300‑bed Gurugram hospital by FY27, 500‑bed Ludhiana by FY28.
• Revenue grew 19.3% CAGR to $193 million in FY26.
• EBITDA surged 47% CAGR to $40 million, boosting profit margins.

Pulse Analysis

India’s healthcare sector is entering a new phase of capital market activity, with specialty hospital operators turning to public listings to fund rapid expansion. Paras Healthcare’s filing marks one of the largest IPOs in the segment, targeting roughly $217 million. By combining a fresh equity issue with a sizable offer‑for‑sale, the company not only raises growth capital but also provides liquidity to its promoters, a structure that aligns shareholder interests with market expectations.

The firm’s growth narrative rests on a blend of organic capacity increases and operational leverage. Adding a 300‑bed facility in Gurugram and a 500‑bed hospital in Ludhiana will push total beds past the 3,000 mark, positioning Paras among the few Indian groups with a truly pan‑regional footprint. This scale‑up is underpinned by a 19.3% revenue CAGR to about $193 million and a striking 47% EBITDA CAGR to $40 million, reflecting higher occupied‑bed days and improved average revenue per occupied bed. Such financial momentum suggests the company can sustain margin expansion as new sites mature.

For investors, Paras Healthcare offers a rare combination of high‑growth revenue, robust profitability, and a clear use‑of‑proceeds roadmap. The IPO proceeds earmarked for debt repayment will strengthen the balance sheet, while the remaining capital fuels strategic expansion in underserved high‑acuity markets. As Indian patients increasingly seek tertiary and quaternary care domestically, the group’s specialty‑led model is well‑positioned to capture discretionary spending, making the offering an attractive play for those betting on the long‑term upside of India’s health‑care infrastructure.